Pieris Pharmaceuticals (PIRS) News Today → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free PIRS Stock Alerts $11.15 -0.01 (-0.09%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineStockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)americanbankingnews.com - May 7 at 3:40 AMPieris Pharmaceuticals (NASDAQ:PIRS) Shares Gap Down to $12.00marketbeat.com - April 24 at 3:35 PMPieris Pharmaceuticals (NASDAQ:PIRS) Sees Large Volume Increasemarketbeat.com - April 23 at 12:31 PMmarketbeat.com - April 23 at 6:06 AMAvalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72Mmsn.com - April 1 at 3:29 AMPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potentialfinanznachrichten.de - March 28 at 2:48 PMPieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potentialfinance.yahoo.com - March 27 at 8:11 AMPIRS Apr 2024 2.500 callfinance.yahoo.com - March 19 at 8:35 PMPieris Pharmaceuticals Inc (PIRS)investing.com - February 10 at 8:42 PMPieris Pharmaceuticals, Inc. (PIRS)finance.yahoo.com - February 1 at 6:10 PMInvestors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%finance.yahoo.com - December 18 at 7:48 AMPieris Pharmaceuticals Inc (PIRS) Earnings Dates & Reportsinvesting.com - November 20 at 1:26 PMPieris Pharmaceuticals Inc PIRSmorningstar.com - November 4 at 1:54 AMPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Whyfinance.yahoo.com - September 25 at 2:43 PMIs Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysisfinance.yahoo.com - August 24 at 5:19 PMPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Knowfinance.yahoo.com - August 23 at 5:43 PMPieris (PIRS) Up On Receiving Milestone Payment From Partnermsn.com - August 18 at 5:30 PMPieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecificfinance.yahoo.com - August 17 at 8:30 AMPieris (PIRS) Pursues Strategic Alternatives, Stock Risesfinance.yahoo.com - July 19 at 2:41 PMPieris Pharma Cuts Around 70% Workforce; Plans Strategic Optionsmarkets.businessinsider.com - July 19 at 9:41 AMPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuringfinanznachrichten.de - July 18 at 2:07 PMWhy Pieris Pharmaceuticals Shares Shooting Higher Today?finance.yahoo.com - July 18 at 2:07 PMPieris Pharmaceuticals Provides Strategic Update and Announces Restructuringfinance.yahoo.com - July 18 at 2:07 PMmarketbeat.com - July 18 at 9:11 AMPieris Pharmaceuticals (NASDAQ: PIRS)fool.com - July 13 at 5:56 PMWhy Are Pieris Pharmaceuticals Shares Tanking Todaymsn.com - June 21 at 2:19 PMPieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Studyfinance.yahoo.com - June 21 at 9:16 AMmarketbeat.com - June 21 at 6:55 AMWe're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Ratefinance.yahoo.com - June 11 at 1:05 PMPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conferencefinanznachrichten.de - June 2 at 6:13 PMPieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conferencefinance.yahoo.com - June 2 at 6:13 PMPieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conferencefinance.yahoo.com - May 22 at 9:22 AMPieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conferencefinance.yahoo.com - May 21 at 8:56 AMPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantiallyfinance.yahoo.com - May 15 at 8:25 AMPieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, revenue of $1.94M misses by $4.57Mseekingalpha.com - May 12 at 12:35 AMPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcriptfinance.yahoo.com - May 11 at 2:34 PMRecap: Pieris Pharmaceuticals Q1 Earningsmsn.com - May 10 at 1:30 PMPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updatesfinanznachrichten.de - May 10 at 8:29 AMPieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updatesfinance.yahoo.com - May 10 at 8:29 AMPreview: Pieris Pharmaceuticals's Earningsmsn.com - May 9 at 5:24 PMPieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The Businessfinance.yahoo.com - May 5 at 9:15 AMPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibepfinanznachrichten.de - May 4 at 1:04 PMPieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)finance.yahoo.com - May 4 at 1:04 PMPieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023finance.yahoo.com - May 2 at 6:11 PMPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa At 2023 AACR Annual Meetingfinanznachrichten.de - April 17 at 5:19 PMPieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meetingfinance.yahoo.com - April 17 at 5:19 PMPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - April 1 at 4:32 PMPieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021)finance.yahoo.com - March 31 at 10:29 AMPieris Pharmaceuticals Clocks 17.6% YoY Revenue Decline In FY22 To $25.9Mbenzinga.com - March 29 at 12:45 PMPieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimatesfinance.yahoo.com - March 29 at 12:45 PM Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address READ THIS – If You Missed Out On The AI Boom (Ad)Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.” Click on Adam's shiny forehead for more details. PIRS Media Mentions By Week PIRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PIRS News Sentiment▼0.300.58▲Average Medical News Sentiment PIRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PIRS Articles This Week▼30▲PIRS Articles Average Week Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Edesa Biotech News NanoViricides News Tonix Pharmaceuticals News Vaxxinity News Kiora Pharmaceuticals News Aytu BioPharma News ABVC BioPharma News Purple Biotech News FSD Pharma News Cocrystal Pharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PIRS) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
